Risk factor
Considerable default risk
Profitability factor
Weak growth
About
Takara Bio Inc., a subsidiary of Takara Holdings Inc., is a Japan-based biotechnology firm established in Kusatsu in 2002. The company operates globally, with a presence in Japan, China, other Asian countries, the United States, and Europe, focusing on three primary areas: general biotechnology, contract development and manufacturing (CDMO) services, and gene therapy. The company offers a diverse portfolio of scientific products, including a wide array of reagents and specialized instruments. These encompass tools for genetic research and testing, in vitro diagnostic solutions for viral detection (such as those for coronaviruses), analytical reagents, and advanced single-cell analysis systems. They also supply essential reagents for gene expression studies, fluorescent protein series, genome-editing research, iPS cell research, and products for culturing and differentiating stem cells. These offerings are marketed under prominent brands like TaKaRa, Clontech, and Cellartis. In addition to its product line, Takara Bio provides extensive contract services. For regenerative medicine, this includes the production of viral vectors and gene-modified cells, alongside rigorous quality and safety testing, and comprehensive cell banking services. Their gene analysis and testing services cover a broad spectrum, from DNA sequencing and gut microbiome analysis to in-depth profiling of cancer-associated genes and the creation of cell lines through genome editing. Furthermore, Takara Bio is actively engaged in developing foundational platform technologies to support the advancement of biologics, particularly within the field of gene therapy.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value
Target Price
The average target price of 4974.T is 1234 and suggests 8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation